Business Description
Upstream Bio Inc
NAICS : 541714
SIC : 8731
ISIN : US91678A1079
Total Employee Number:
75Description
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 264.43 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 14.67 | |||||
Beneish M-Score | -2.47 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 17.1 | |||||
3-Year EBITDA Growth Rate | -65.3 | |||||
3-Year EPS without NRI Growth Rate | -59.4 | |||||
3-Year FCF Growth Rate | -67.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -5.39 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.33 | |||||
9-Day RSI | 42.46 | |||||
14-Day RSI | 44.75 | |||||
3-1 Month Momentum % | -38.44 | |||||
6-1 Month Momentum % | -80.16 | |||||
12-1 Month Momentum % | -44.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 23.14 | |||||
Quick Ratio | 23.14 | |||||
Cash Ratio | 21.55 | |||||
Days Sales Outstanding | 85.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | -0.03 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -5176.49 | |||||
Net Margin % | -4718.96 | |||||
EBITDA Margin % | -5170.65 | |||||
FCF Margin % | -4213.18 | |||||
OCF Margin % | -4213.18 | |||||
ROE % | -41.77 | |||||
ROA % | -40.41 | |||||
ROIC % | -1308.04 | |||||
3-Year ROIIC % | -2378.87 | |||||
ROC (Joel Greenblatt) % | -1881.93 | |||||
ROCE % | -45.73 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 114.95 | |||||
PB Ratio | 1.25 | |||||
Price-to-Tangible-Book | 1.25 | |||||
EV-to-EBIT | -0.51 | |||||
EV-to-EBITDA | -0.51 | |||||
EV-to-Revenue | 26.5 | |||||
EV-to-Forward-Revenue | 39.23 | |||||
EV-to-FCF | -0.63 | |||||
| Price-to-Net-Current-Asset-Value | 1.26 | |||||
| Price-to-Net-Cash | 1.36 | |||||
Earnings Yield (Greenblatt) % | -196.08 | |||||
FCF Yield % | -36.69 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:UPB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Upstream Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.322 | ||
| EPS (TTM) ($) | -2.903 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 103.27 | ||
| 14-Day RSI | 44.75 | ||
| 14-Day ATR ($) | 0.438058 | ||
| 20-Day SMA ($) | 7.073 | ||
| 12-1 Month Momentum % | -44.29 | ||
| 52-Week Range ($) | 5.85 - 33.68 | ||
| Shares Outstanding (Mil) | 54.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Upstream Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Upstream Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 110 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 19 days | ||
| Goldman Sachs 47(th) Annual Global Healthcare Conference | 2026-06-10 10:40 | 6.69 (+2.45%) | ||
| General meeting for 2026 | 2026-06-09 09:00 | 6.45 (-9.92%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 8.95 (+0.22%) | ||
| Annual report for 2025 | 2026-03-26 | 9.47 (+8.23%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 9.47 (+8.23%) | ||
| Guidance call for 2026 | 2026-03-09 13:40 | 7.66 (+2.54%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-04 09:50 | 7.36 (-2.97%) | ||
| 44(th) Annual J.P. Morgan Healthcare Conference | 2026-01-12 14:15 | 29.75 (+6.75%) |
Show
Entries
Upstream Bio Inc Frequently Asked Questions
What is Upstream Bio Inc(UPB)'s stock price today?
The current price of UPB is $6.99. The 52 week high of UPB is $33.68 and 52 week low is $5.85.
When is next earnings date of Upstream Bio Inc(UPB)?
The next earnings date of Upstream Bio Inc(UPB) is 2026-08-06 Est..
Does Upstream Bio Inc(UPB) pay dividends? If so, how much?
Upstream Bio Inc(UPB) does not pay dividend.
Guru Commentaries on NAS:UPB
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Automotive Security Leaders Must Take Immediate Action to Mitigate the Surging Cyber Threats--Upstream Report Reveals Critical Gaps | 2025-02-11 |
Articles on Upstream Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers